BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36981015)

  • 21. Novel missense mutation in the FH gene in familial renal cell cancer patients lacking cutaneous leiomyomas.
    Kuwada M; Chihara Y; Lou Y; Torimoto K; Kagebayashi Y; Tamura K; Shuin T; Fujimoto K; Kuniyasu H; Samma S
    BMC Res Notes; 2014 Mar; 7():203. PubMed ID: 24684806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
    Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
    Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel fumarate hydratase mutation in a family with atypical uterine leiomyomas and hereditary leiomyomatosis and renal cell cancer.
    Wheeler KC; Warr DJ; Warsetsky SI; Barmat LI
    Fertil Steril; 2016 Jan; 105(1):144-8. PubMed ID: 26493120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
    Bhola PT; Gilpin C; Smith A; Graham GE
    Fam Cancer; 2018 Oct; 17(4):615-620. PubMed ID: 29423582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.
    Wei MH; Toure O; Glenn GM; Pithukpakorn M; Neckers L; Stolle C; Choyke P; Grubb R; Middelton L; Turner ML; Walther MM; Merino MJ; Zbar B; Linehan WM; Toro JR
    J Med Genet; 2006 Jan; 43(1):18-27. PubMed ID: 15937070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.
    Smit DL; Mensenkamp AR; Badeloe S; Breuning MH; Simon ME; van Spaendonck KY; Aalfs CM; Post JG; Shanley S; Krapels IP; Hoefsloot LH; van Moorselaar RJ; Starink TM; Bayley JP; Frank J; van Steensel MA; Menko FH
    Clin Genet; 2011 Jan; 79(1):49-59. PubMed ID: 20618355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel missense mutation in fumarate hydratase in an Italian patient with a diffuse variant of cutaneous leiomyomatosis (Reed's syndrome).
    Rongioletti F; Fausti V; Ferrando B; Parodi A; Mandich P; Pasini B
    Dermatology; 2010; 221(4):378-80. PubMed ID: 21051878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
    Toro JR; Nickerson ML; Wei MH; Warren MB; Glenn GM; Turner ML; Stewart L; Duray P; Tourre O; Sharma N; Choyke P; Stratton P; Merino M; Walther MM; Linehan WM; Schmidt LS; Zbar B
    Am J Hum Genet; 2003 Jul; 73(1):95-106. PubMed ID: 12772087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fumarate Hydratase is a Novel Gene for Familial Non-Medullary Thyroid Cancer.
    Alzahrani AS; Alswailem M; Alghamdi B; Al-Hindi H
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2539-2544. PubMed ID: 35751867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
    Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
    BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
    Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
    Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological and molecular characteristics of fumarate hydratase-deficient uterine smooth muscle tumors: a single-center study of 52 cases.
    Li H; Yang W; Tu X; Yu L; Huang D; Cheng Y; Chang B; Tang S; Ge H; Bao L; Zhou X; Bi R
    Hum Pathol; 2022 Aug; 126():136-145. PubMed ID: 35659509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fumarate Hydratase-Deficient Leiomyoma of the Uterine Corpus: Comparative Morphologic Analysis of Protein-Deficient Tumors With and Without Pathogenic Germline Fumarate Hydratase Gene Mutations.
    Shi W; Liu Y; Aisagbonhi O; Roma AA; Hasteh F; Zare SY; Fadare O
    Int J Surg Pathol; 2024 Apr; 32(2):340-355. PubMed ID: 37312573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
    Bayley JP; Launonen V; Tomlinson IP
    BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.
    Vahteristo P; Koski TA; Näätsaari L; Kiuru M; Karhu A; Herva R; Sallinen SL; Vierimaa O; Björck E; Richard S; Gardie B; Bessis D; Van Glabeke E; Blanco I; Houlston R; Senter L; Hietala M; Aittomäki K; Aaltonen LA; Launonen V; Lehtonen R
    Fam Cancer; 2010 Jun; 9(2):245-51. PubMed ID: 20091131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer.
    Alam NA; Olpin S; Leigh IM
    Br J Dermatol; 2005 Jul; 153(1):11-7. PubMed ID: 16029320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Fumarate Hydratase Mutation in Siblings With Early Onset Uterine Leiomyomas and Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome.
    Gunnala V; Pereira N; Irani M; Lilienthal D; Pirog EC; Soslow R; Caputo TA; Elias R; Kligman I; Rosenwaks Z
    Int J Gynecol Pathol; 2018 May; 37(3):256-261. PubMed ID: 28700432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
    Plevová P; Hladíková A; Tesařová M
    Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.